Literature DB >> 9008462

Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition.

E Van Belle1, F O Tio, T Couffinhal, L Maillard, J Passeri, J M Isner.   

Abstract

BACKGROUND: Because prior studies have established the critical role of the endothelium in preventing vascular thrombosis and intimal thickening, we designed a series of experiments to determine the feasibility of percutaneous local catheter delivery of recombinant protein to accelerate development of an intact endothelial monolayer after stent implantation. METHODS AND
RESULTS: Balloon injury followed by percutaneous delivery of a 15-mm-long, balloon-expandable metallic stent was performed in 64 rabbit external iliac arteries (baseline diameter, 2.67 +/- 0.07 mm). Planimetric time-course analysis disclosed < 20% stent endothelialization at 4 days, < 40% at 7 days, and near-complete endothelialization at 28 days. The reporter protein horseradish peroxidase and the endothelial cell-specific recombinant protein vascular endothelial growth factor (VEGF) were each effectively delivered from a local delivery catheter (channel balloon catheter, ChB) after stent implantation. Although local catheter delivery (of vehicle control) itself mildly retarded the extent of stent endothelialization (10.6 +/- 2.9%) versus no local delivery (25.5 +/- 6.6%, P = .045), local ChB delivery of 100 micrograms VEGF overcame this catheter effect: By day 7, stent endothelialization was nearly complete (91.8 +/- 3.8%) (P < .0001 versus no local delivery). Consequently, stent thrombus was reduced in the VEGF-treated group (mural thrombus, 5.3 +/- 3.7%) versus no local delivery (29.3 +/- 6.8%, P = .006). Occlusive thrombus was seen only in the absence of local VEGF administration.
CONCLUSIONS: (1) Local delivery of recombinant protein to the arterial wall is feasible after stent implantation, and (2) local delivery of the endothelial cell mitogen VEGF accelerates stent endothelialization, reducing stent thrombosis. These results thus establish a novel means by which the safety and/or bioactivity of endovascular stents may be further enhanced.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008462     DOI: 10.1161/01.cir.95.2.438

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

Authors:  T Couffinhal; M Kearney; B Witzenbichler; D Chen; T Murohara; D W Losordo; J Symes; J M Isner
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Minimally invasive endovascular stent-electrode array for high-fidelity, chronic recordings of cortical neural activity.

Authors:  Thomas J Oxley; Nicholas L Opie; Sam E John; Gil S Rind; Stephen M Ronayne; Tracey L Wheeler; Jack W Judy; Alan J McDonald; Anthony Dornom; Timothy J H Lovell; Christopher Steward; David J Garrett; Bradford A Moffat; Elaine H Lui; Nawaf Yassi; Bruce C V Campbell; Yan T Wong; Kate E Fox; Ewan S Nurse; Iwan E Bennett; Sébastien H Bauquier; Kishan A Liyanage; Nicole R van der Nagel; Piero Perucca; Arman Ahnood; Katherine P Gill; Bernard Yan; Leonid Churilov; Christopher R French; Patricia M Desmond; Malcolm K Horne; Lynette Kiers; Steven Prawer; Stephen M Davis; Anthony N Burkitt; Peter J Mitchell; David B Grayden; Clive N May; Terence J O'Brien
Journal:  Nat Biotechnol       Date:  2016-02-08       Impact factor: 54.908

3.  Granulation encapsulated stent: a new therapeutic approach for vascular implantation.

Authors:  Lilong Tang; Xiaochao Chen; Shuangbo Tang; Thomas LaLonde; Julius M Gardin
Journal:  Heart       Date:  2006-08-16       Impact factor: 5.994

4.  VEGF polymorphisms and severity of atherosclerosis.

Authors:  W M Howell; S Ali; M J Rose-Zerilli; S Ye
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

Review 5.  Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury.

Authors:  Austin I McDonald; M Luisa Iruela-Arispe
Journal:  Vascul Pharmacol       Date:  2015-06-18       Impact factor: 5.773

Review 6.  Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

Authors:  Pramod Kuchulakanti; Ron Waksman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Chemical activation and changes in surface morphology of poly(ε-caprolactone) modulate VEGF responsiveness of human endothelial cells.

Authors:  Thilo Storm; Katharina Wulf; Michael Teske; Marian Löbler; Günther Kundt; Frank Luderer; Klaus-Peter Schmitz; Katrin Sternberg; Marina Hovakimyan
Journal:  J Mater Sci Mater Med       Date:  2014-05-09       Impact factor: 3.896

Review 8.  Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances.

Authors:  Fei Wu; Tuo Jin
Journal:  AAPS PharmSciTech       Date:  2008-12-16       Impact factor: 3.246

9.  Endothelial Cellular Responses to Biodegradable Metal Zinc.

Authors:  Jun Ma; Nan Zhao; Donghui Zhu
Journal:  ACS Biomater Sci Eng       Date:  2015-09-17

10.  Surface projections of titanium substrates increase antithrombotic endothelial function in response to shear stress.

Authors:  Alexandra E Jantzen; Hardean E Achneck; George A Truskey
Journal:  J Biomed Mater Res A       Date:  2013-04-02       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.